As Senior Vice President, Head of Rare Tumors, North America, Venkat oversees all aspects of the Rare Tumors brand strategies and execution for the newly launched products, OGSIVEO and GOMEKLI. Prior to this, Venkat served as Senior Vice President of U.S. Neurology and Immunology (N&I) for EMD Serono, where he was responsible for leading the strategic direction and growth of its $1B+ N&I business in the U.S. and in establishing MAVENCLAD® as the #1 new-to-brand oral in MS.

Venkat joined EMD Serono in 2014 and has held a variety of roles of increasing responsibility within the Global and U.S. N&I organizations. In his role as Vice President and Head of Marketing for N&I, Venkat helped launch MAVENCLAD, an oral therapy helping it achieve blockbuster status and was instrumental in the company’s growth in the multiple sclerosis market. Having started his career as an engineer, he brings a unique approach to his work.

Venkat holds a Master of Science degree in Chemical Engineering from West Virginia University and a Master’s in Business Administration in Strategy, Marketing and Corporate Finance from the Leonard N. Stern School of Business, New York.